Eighty-one patients with primary bone malignancy, including Ewing’s sarcoma (58%), chondrosarcoma (7.4%), chordoma (24.7%), osteosarcoma (7.4%), and osteoblastoma (2.5%), of the pelvis and lumbar spine treated with PT. With a median follow up of 27.5 months, 2-year and 3-year OS for all patients in this cohort were 88.1 and 68.9%, respectively. 2-year and 3-year LC were 76.5 and 72.9%, respectively. Higher-grade late toxicities were found in seven out of 67 patients (10.4%).